idea-001 · narrative

A synthesis across this candidate's claims, dossier and decks — every statement here traces to something that already exists elsewhere in the knowledge base. A narrative never invents a fact, upgrades a tag, or recommends anything.

Home Stress-Incontinence Stimulator (pivot P2, two-channel trigger) — the story so far

How to read this. This is a synthesis, not a new source of truth. Every claim it cites carries the tag the candidate file gives it right now, copied and not paraphrased. Every line quoted from a deck is quoted verbatim. A line marked as dossier context is context, not evidence. See docs/narrative-spec.md.

Rebuilt 2026-10-01 after pivot P2 the discriminating trigger, not patched. The previous narrative described P1 commercially-insured first's mechanism and carried tags that have since moved. It is retired. This one was written from the candidate file, the stress-urinary-incontinence dossier and the three decks as they stand today. The candidate's seeds: field is absent, so no macro-trend seed was read.

On how much this says about the trigger. The candidate's own IP (intellectual property) claims treat the withhold logic as possibly new, and nobody has settled that claim 198unconfirmed, claim 199unconfirmed. So this narrative describes the trigger only at the level of the candidate's mechanism: field and adds no implementation detail.

The one-paragraph version

This is a prescription home device for cognitively intact adult women with stress urinary incontinence whose documented four-week exercise trial has failed. It is an intravaginal stimulator whose stimulation fires on a voluntary pelvic floor contraction. It withholds a burst when a two-channel detector sees a Valsalva manoeuvre or abdominal brace before that burst. The second channel is an abdominal skin electrode the woman places herself each session. The device took this shape on 2026-10-01 because its original premise was refuted. A prescription EMG (electromyography)-triggered intravaginal stimulator for incontinence is already listed and offered for sale in the US claim 167refuted. So the closed loop is no longer this device's difference, and the withhold on a strain is now the only one. The route is well established for the device class: a Class II (FDA device class II) 510(k) (premarket notification) code claim 1verified, two verified predicates that carry a triggered mode claim 153verified, claim 154verified, a Medicare code and coverage policy claim 7verified, claim 9verified, and a fixed monthly rental that pays the same whatever the device does claim 193verified. Nothing about the difference itself is established. Nobody has checked whether the sold devices already do it, whether it works, or whether a prescriber wants it.

The story so far

The problem and the moment. The intended use is "the treatment of stress urinary incontinence in cognitively intact adult women in the home setting, by prescription, following a documented failed four-week trial of pelvic muscle exercise training". Its precondition mirrors Medicare's own coverage criterion claim 9verified. That precondition does no FDA (US Food and Drug Administration) classification or predicate work, so removing it would leave the route unchanged claim 156verified. In NHANES data, weighted urinary incontinence prevalence among US women is 22.3%, with stress-predominant incontinence 16.2% of cases claim 44unconfirmed. The dossier warns against multiplying those two figures into a population prevalence the source paper never computed [dossier: stress-urinary-incontinence]. Exercise training is first-line and hard to sustain. Long-term adherence ranges from 10% to 70% across studies claim 39unconfirmed. In the one study that asked, forgetting and boredom were the reasons most strongly tied to low adherence [dossier: stress-urinary-incontinence]. Whether women who fail the four-week trial stay in care at all is not known claim 26unconfirmed.

The original shape, and what broke it. The candidate began as a home stimulator with EMG sensing, built around closing the loop between muscle activity and stimulation. Its first pivot, P1 commercially-insured first, moved the launch payer to commercially insured women. That followed two refutations of guessed Medicare volumes. CPT (Current Procedural Terminology) 90912 services were claimed to exceed 200,000 a year claim 16refuted, and E0740 (a HCPCS code for durable medical equipment) units to exceed 10,000 a year claim 17refuted. Both refute the asserted number, not the service. The verified 2024 floor is 689 fee-for-service beneficiaries for E0740 claim 70verified. Then, on 2026-10-01, two KPI clearances that carry an EMG-triggered stimulation mode through a vaginal probe were verified as predicates claim 153verified, claim 154verified. The same day the premise that no such device is sold in the US came back refuted on the MyOnyx claim 167refuted. The candidate's mechanism: field records the change as pivot P2 the discriminating trigger and quotes the old text beside the new.

The mechanism now. Per the mechanism: field, the probe delivers neuromuscular electrical stimulation. Each burst fires on a voluntary pelvic floor contraction and is withheld when the detector sees a Valsalva manoeuvre or abdominal brace before the burst. The decision is taken before each burst, so a strain that begins during a burst is outside the mechanism. The case for a second channel is that vaginal pelvic floor EMG also rises during a Valsalva and a brace, and symptomatic women show more of it claim 150unconfirmed. Vaginal pressure did not separate the two manoeuvres in one small study either claim 151unconfirmed. The case against easy success is that abdominal activity also rises on a correct contraction claim 177unconfirmed, claim 203unconfirmed. Nobody has measured how well any two-channel detector separates the manoeuvres claim 204unconfirmed, and nobody has measured it for a single channel either claim 105unconfirmed. Whether a burst delivered during a strain does any harm beyond a lost training effect is on record and unchecked claim 209unverified.

Why now (context only). The file holds no macro-trend seed. The "why now" it does carry is an event: the incumbents' triggered mode was verified as cleared and shown to be sold claim 153verified, claim 167refuted. That made a difference within triggered stimulation the only remaining differentiation question.

What has been checked, and what has not. The regulatory and coverage setting has been checked hardest. The incumbents' trigger logic is half-checked. Where a cleared summary describes how its trigger fires, it describes a threshold on pelvic floor EMG alone. Cleared ETS (electrical tissue stimulation) hardware already carries a second EMG channel, so at summary level P2 the discriminating trigger adds detector logic and a skin electrode, not new sensing hardware claim 202verified. Whether any of the four cleared ETS devices uses a reference channel is unsettled, and the MyOnyx app can run two EMG channels claim 173unconfirmed. The people this depends on have not been asked. That covers the prescriber claim 174unconfirmed, the woman placing the electrode claim 172unconfirmed, and the supplier claim 170unconfirmed. The economics also cut against differentiation. The Medicare allowable is the same for this trigger as for a single-channel or stimulation-only device claim 193verified.

A source that has fallen behind. The candidate file's own ## Wrap section predates P2 the discriminating trigger. It quotes the P1 commercially-insured first-era decks' load-bearing conditions and cites claim 167refuted with a tag the file no longer carries. This narrative quotes the decks rebuilt for P2 the discriminating trigger and leaves the Wrap section alone. Rewriting it is /wrap's job.

What's solid

Every line below is a claim the candidate tags verified. Each one is about the setting: the device class, the code, the coverage, the money, the incumbents. None of them is about whether the P2 the discriminating trigger difference exists, works, or is wanted.

Regulatory class and predicates

Coding, coverage and payment

Volume (a floor, not a market)

What's still open

Refuted, stated plainly

Whether P2 the discriminating trigger's difference is real

Whether it works

Whether it is wanted

Whether the money works

Freedom to operate

Dossier context, not evidence

Where the three lenses agree — and where they don't

All three decks exist. All three were rebuilt on 2026-10-01 for P2 the discriminating trigger, and check_decks.py passes all three, so none is stale. They agree on the frame. The closed loop is already sold claim 167refuted, and P2 the discriminating trigger stands or falls on one difference: withholding a burst on a Valsalva or brace. Each deck then puts its weight on a different face of that difference. Each also says every one of its conditions rests on unconfirmed or unverified lines.

Desirability (built 2026-10-01; current). The user's chair treats the difference as a cost the woman pays every session. That cost is an electrode to place, a skin reaction, and bursts withheld on efforts she believes were correct. The deck asks who would value the difference enough to impose that cost. It names the prescriber as the first person who has to say yes, because she alone decides whether the woman ever meets the device. It shares with the viability deck an unmeasured number: how many women still strain at the label's moment claim 176unconfirmed. It hands its money questions to viability.

"whether a urogynecologist or pelvic floor PT (physical therapist) who has already decided on a home EMG-triggered stimulator would choose one whose trigger uses an abdominal electrode the woman places herself each session, to withhold stimulation on a Valsalva or brace, over a cleared single-channel triggered device such as the NeuroTrac MyoPlus Pro, despite the extra electrode" — the load-bearing condition of the desirability deck (built 2026-10-01).

Viability (built 2026-10-01; current). The investor's chair agrees the difference is the whole case. It adds that the verified money facts cut against it. The Medicare allowable is the same with or without the difference claim 193verified. Cleared hardware already has the second channel, so a copier's barrier would be firmware and possibly a new 510(k) claim 202verified, claim 213unverified. Where it departs from desirability is on order. It asks first whether the difference exists at all. If an incumbent already withholds, the prescriber question describes a me-too. The deck names that link itself. It states that the demand half of its question is desirability's load-bearing condition.

"whether any of the cleared, sold EMG-triggered stimulators for incontinence already uses an abdominal or other reference channel in deciding when to fire. The MyOnyx in particular matters, because its app can run two EMG channels" — the load-bearing condition of the viability deck (built 2026-10-01).

Feasibility (built 2026-10-01; current). Engineering's chair agrees the difference is the only one. It says the function behind it has never been measured in any configuration. It treats the route, the bench work, the electrode supply and FTO (freedom to operate) as conditional on discrimination working. Its open disagreement with the other two lenses is about what a clean answer to their questions would buy. If no incumbent uses a reference channel and prescribers say they want one, the device can still fail on separating the manoeuvres. The deck states the converse plainly too: discrimination that works but changes no outcome is "real and clinically empty". Like the user deck, it describes the trigger only at the level of the mechanism: field.

"whether a two-channel detector, pelvic floor surface EMG from the probe plus an abdominal reference from a skin electrode the woman places herself, separates a voluntary pelvic floor contraction from a Valsalva or abdominal brace with usable specificity, and keeps doing so when she places the electrode imperfectly" — the load-bearing condition of the feasibility deck (built 2026-10-01).

Where they disagree. The disagreement is not about facts. It is about which face of the one difference to check first. Viability asks whether it is unique claim 173unconfirmed. Desirability asks whether it is wanted claim 174unconfirmed. Feasibility asks whether it works claim 204unconfirmed. Each deck calls its own check cheap: two manual reads, twenty calls, and a sensing-only study on a cleared device. No deck claims its answer would settle the other two.

The load-bearing question

Is P2 the discriminating trigger's one difference real in all three senses the decks name? That is, a withheld burst when the detector sees a Valsalva or brace that (a) no sold triggered device already provides, (b) a self-placed two-channel detector can actually deliver in women who have failed a four-week exercise trial, and (c) a prescriber who can already prescribe a single-channel triggered device would choose despite the extra electrode? The closed loop alone is already on sale claim 167refuted, and the Medicare allowable does not reward the difference claim 193verified. So each of those three senses is a condition the candidate needs, and none of them has yet been checked claim 173unconfirmed, claim 204unconfirmed, claim 174unconfirmed.

Naming this question is not a recommendation, a gate, or a kill. Which part to check first, and whether to spend on any of it, is a human's call.

Words on this page23 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md
21 CFR
Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k)
premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
Class II
FDA device class II — moderate-risk devices, usually cleared by 510(k)
CMS
Centers for Medicare & Medicaid Services — the US agency that runs Medicare, and so decides what Medicare pays for
CPT
Current Procedural Terminology — the US billing codes for what a clinician does; owned by the American Medical Association
DME
durable medical equipment — equipment a patient uses at home, such as a pump or a stimulator, that Medicare pays for under its own rules
DMEPOS
durable medical equipment, prosthetics, orthotics and supplies — the Medicare benefit and fee schedule that home equipment is paid under
E####
a HCPCS code for durable medical equipment — one billing code for a piece of home equipment; the letter E and four digits
EMG
electromyography — reading the electrical activity of a muscle
ETS
electrical tissue stimulation — the FDA's name for the product family of stimulators
FDA
US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
FTO
freedom to operate — whether a product can be sold without infringing someone else's live patent
HCPCS
Healthcare Common Procedure Coding System — the US billing codes for equipment, supplies and some services; a code is how a payer recognises what to pay for
IP
intellectual property — patents and the other rights that let a company stop others copying it
K######
an FDA 510(k) clearance number — the public record of one cleared device; the letter K and six digits
MAUDE
Manufacturer and User Facility Device Experience — the FDA's public database of reported device problems
Medicare Advantage
Medicare Advantage — Medicare delivered through a private insurer; must cover at least what Medicare covers
Medicare Part B
Medicare Part B — the part of Medicare that pays for outpatient care and equipment used at home
NCD
national coverage determination — a Medicare rule, valid everywhere in the US, saying whether and when something is covered
NCD ###.#
a Medicare national coverage determination number — the public id of one national coverage rule
PDAC
Pricing, Data Analysis and Coding contractor — the Medicare contractor that decides which billing code a specific product falls under
PT
physical therapist — a physiotherapist
RVU
relative value unit — the unit Medicare uses to price a clinician's work
Generated from knowledge-base/narratives/idea-001.md by engine/scripts/build_review.py on 2026-10-04. This page is a view — edit the source file and rebuild, never edit here.